RESEARCH ARTICLE

Reverse mutants of the catalytic 19 kDa mutant protein (nanoKAZ/nanoLuc) from Oplophorus luciferase with coelenterazine as preferred substrate

Satoshi Inouye1,*, Jun-ichi Sato1, Yuiko Sahara-Miura1, Yuri Tomabechi2, Yuto Sumida3,*, Shun-ichi Sekine4, Mikako Shirouzu2, Takamitsu Hosoya3,5

1 Yokohama Research Center, JNC Co., Kanazawa-ku, Yokohama, Japan, 2 Laboratory for Protein Functional and Structural Biology, RIKEN Center for Biosystems Dynamics Research (BDR), Tsurumi-ku, Yokohama, Japan, 3 Laboratory for Chemical Biology, RIKEN Center for Biosystems Dynamics Research (BDR), Chuo-ku, Kobe, Japan, 4 Laboratory for Transcription Structural Biology, RIKEN Center for Biosystems Dynamics Research (BDR), Tsurumi-ku, Yokohama, Japan, 5 Laboratory of Chemical Bioscience, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU), Chiyoda-ku, Tokyo, Japan

* Current address: Division of Pharmaceutical Sciences, Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Japan

* sinouye@jnc-corp.co.jp

Abstract

Native Oplophorus luciferase (OpLase) and its catalytic 19 kDa protein (wild KAZ) show highest luminescence activity with coelenterazine (CTZ) among CTZ analogs. Mutated wild KAZ with 16 amino acid substitutions (nanoKAZ/nanoLuc) utilizes bis-coelenterazine (bis-CTZ) as the preferred substrate and exhibits over 10-fold higher maximum intensity than CTZ. To understand the substrate selectivity of nanoKAZ between CTZ and bis-CTZ, we prepared the reverse mutants of nanoKAZ by amino acid replacements with the original amino acid residue of wild KAZ. The reverse mutant with L18Q and V27L substitutions (QL-nanoKAZ) exhibited 2.6-fold higher maximum intensity with CTZ than that of nanoKAZ with bis-CTZ. The catalytic properties of QL-nanoKAZ including substrate specificity, luminescence spectrum, luminescence kinetics, luminescence products of CTZ, and luminescence inhibition by deaza-CTZ analogs were characterized and were compared with other CTZ-utilizing luciferases such as Gaussia and Renilla luciferases. Thus, QL-nanoKAZ with CTZ could be used as a potential reporter protein for various luminescence assay systems. Furthermore, the crystal structure of QL-nanoKAZ was determined at 1.70 Å resolution. The reverse mutation at the L18Q and V27L positions of α2-helix in nanoKAZ led to changes in the local structures of the α4-helix and the β6- and β7-sheets, and might enhance its binding affinity and oxidation efficiency with CTZ to emit light.

Introduction

Oplophorus luciferase (OpLase) is a secretory protein isolated from the deep-sea shrimp, Oplophorus gracilirostris, and catalyzes the oxidation of coelenterazine (CTZ, a luciferin) to emit...
support in the form of authors' salaries [SI, JS, YM] and/or research materials.

Competing interests: Satoshi Inouye, Jun-ichi Sato, and Yuiko Sahara-Miura are employees in JNC Corporation. JNC did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Abbreviations: OpLase, Oplophorus luciferase; KAZ, the catalytic 19 kDa protein of OpLase; nanoKAZ (= nanoLuc), a KAZ mutant with 16-amino acid substitutions; QL-nanoKAZ, a nanoKAZ mutant reversed to L18Q and V27L; SNH-nanoKAZ (= telLuc), a mutant of nanoKAZ with D19S, D85N, C169H; RLase, Renilla luciferase; RLase-547 (= RLuc8.6–547), Renilla luciferase mutant with an emission peak at 547 nm; GLase, Gaussia luciferase; GLsp, the signal peptide sequence of GLase; RLBP, Renilla luciferin-binding protein; apoAequorin, apoprotein of aequorin; CTZ, coelenterazine; CTZ-OOH, 2-peroxycoelenterazine; CTMD, coelenteramidine; CTM, coelenteramine; CTO, 3-benzyl-5-(4-hydroxyphenyl)pyrazin-2(1H)-one; dCTZ, dehydrocoelenterazine; FMZ, furimazine; daCTZ, deaza-coelenterazine; Int, integrated luminescence intensity in 0.1 s-intervals; \( \lambda_{max} \), maximum wavelength of luminescence; FWHM, a full width of half maximum rlu, relative light units;

Materials and methods

Materials

The sources of chemicals were as follows: isopropyl β-thiogalactopyranoside (IPTG), ethylenediaminetetraacetic acid disodium salt (EDTA•2Na), (±)-dithiothreitol (DTT), and imidazole (Wako Pure Chemicals, Osaka, Japan); chelate Sepharose Fast Flow (GE-Healthcare Bio-Science, Piscataway, NJ, USA); coelenterazine (CTZ), coelenteramine (CTM), coelenteramide (CTMD), h-coelenterazine (h-CTZ), bis-coelenterazine (bis-CTZ), and f-coelenterazine (f-CTZ) (JNC Co., Tokyo, Japan). 6h-Coelenterazine (6h-CTZ), 6h-f-coelenterazine (6h-f-CTZ), and furimazine (FMZ) were synthesized as previously reported [5] (Fig 1B). The syntheses of the C2-modified CTZ analogs [20] (Fig 1B) and deaza-CTZ analogs [19] (Fig 1C) were
described in our previous reports. Oligonucleotides used for site-directed mutagenesis and the synthetic gene of SNH-nanoKAZ (a nanoKAZ mutant with three amino acid substitutions; D19S, D85N, and C169H) which has the identical amino acid sequence to telLuc [15]), were obtained from Eurofins Genomics (Tokyo, Japan). Native OpLase (Lot. 20011221-red labeled

Fig 1. Luminescence reaction of coelenterazine (CTZ) catalyzed by the CTZ-utilizing luciferase and chemical structures of CTZ analogs and deaza-CTZ analogs. A. Oxidation process of CTZ with O2 by CTZ-utilizing luciferases and the degradation product of coelenteramine (CTM), 4-hydroxyphenylacetic acid (4HPAA), and 4-hydroxyphenylpyruvic acid (4HPPA) through 2-peroxycoelenterazine (CTZ-OOH). B. Chemical structures of C2- and C6-modified CTZ analogs. The C6-group of CTZ analogs was colored in red, and the C2- and C8-groups of CTZ analogs were colored in blue. C. Chemical structures of deaza-analogs for CTZ and CTZ-OOH as inhibitors.

https://doi.org/10.1371/journal.pone.0272992.g001
fraction, >90% purity) was kindly provided by Dr. Osamu Shimomura (Marine Biology Laboratory, Woods Hole, MA, USA).

**Recombinant luciferases**

Recombinant histidine-tagged luciferases for RLase [17], RLase-547 (a mutant of RLase with an emission peak at 547 nm, known as RLuc8.6–547 [18]), nanoKAZ (a mutant with 16 amino acids substituted in wild KAZ [3] obtained from the preferred human-codon optimized gene [5]), and SNH-nanoKAZ [15] were expressed in the cytoplasm of *E. coli* strain BL21 (Novagen, Madison, WI) using a cold induction system with the expression vectors of pCold-RL [13], pCold-RL 547 [13], pCold-dnKAZ [10], pCold-QL-nanoKAZ (this work), and pCold-SNH-nanoKAZ (this work), and purified using a Ni-chelate column, as previously described [10,13]. Recombinant GLase with the histidine-tagged sequence at the carboxyl terminus was stably expressed into the culture medium from a dihydrofolate reductase-deficient Chinese hamster ovary cells (CHO-K1/dhfr− cells) possessing a pcDNA3-hGL-H vector and was purified from the serum-containing cultured medium using a Ni-chelate column [21].

**Preparation of mutated genes for nanoKAZ**

The chimeric genes for wild KAZ (wK), nanoKAZ (nK), and their reverse mutants were prepared as follows:

i) The chimeric genes for wK/nK chimera and nK/wK chimera were prepared by replacing the EcoRI-Sall fragment (amino acid residues 1–82) or Sall-XbaI fragment (amino acid residues 83–169) of wild KAZ with the corresponding fragments of nanoKAZ, respectively (Fig 2A).

ii) The reverse mutant genes of wK/nK chimera (Fig 2B) and nanoKAZ (Fig 2C–2E) were prepared by site-directed mutagenesis using the overlap extension polymerase chain reaction (PCR) procedures [22] with the specific primers (S1 Table). The nucleotide sequences of mutated genes were confirmed by DNA sequencing (Eurofins Genomics).

**Expression of mutated proteins in bacterial cells**

The cold-inducible expression vector of pCold-ZZ-P-X under the control of the cold shock protein A promoter and the lac operator in *E. coli* cells [23,24] was used to express as a fused protein of the ZZ domain, which is the synthetic IgG-binding domain of staphylococcal protein A and serves as a soluble partner of target proteins [23,24]. The vector consists of a histidine tag sequence for Ni-chelate affinity chromatography, the cleavage sequence of human rhinovirus 3C protease between the ZZ domain and a target protein, followed by the multiple cloning sites [24]. The EcoRI-XbaI fragment of the reverse mutated gene was inserted into the EcoRI-XbaI site of a pCold-ZZ-P-X vector to give the corresponding expression vector.

To determine luminescence activity of reverse mutants, the seed culture of *E. coli* strain BL21 possessing each expression vector was grown in 5 mL of Luria-Bertani broth (LB broth) containing ampicillin (50 μg/mL) at 37˚C for 18 h using a TAIITEC model BR-3000LF shaker (Tokyo, Japan) with reciprocal shaking (130 rpm). After transferring 0.1 mL of the seed culture to 10 mL of LB broth, the bacterial cells were cultured at 37˚C for 3 h and then cooled on an ice bath over 30 min. To induce protein expression, 1 M IPTG was added to the culture medium at a final concentration of 1 mM and the bacterial cells were cultured at 15˚C for 20 h. After collecting 1 mL of cultured cells using a TOMY model MCX-150 micro-centrifuge (Tokyo, Japan) at 8,000 rpm for 30 s, cells were suspended in 0.5 mL of 50 mM Tris-HCl (pH 7.6) and disrupted by sonication using a Branson model 250 sonifier (Danbury, CT) for 5 s in an ice-water bath. The soluble fraction of cell extracts obtained by centrifugation at 12,000 × g
for 3 min was used for determining the luminescence activity and 5 μL was subjected to SDS-PAGE analysis (Fig 3).

Expression and purification of QL-nanoKAZ and SNH-nanoKAZ

For purification of QL-nanoKAZ, the EcoRI-XbaI fragment of 18Q27L-nanoKAZ gene was replaced with nanoKAZ gene in pCold-dnKAZ [10] to give an expression vector, pCold-QL-
The expressed QL-nanoKAZ consisted of 191 amino acid residues having the amino-terminal sequence of MNHKVHHHHHHMLEGTLEGSEF (histidine-tag sequence underlined). The purification was carried out using Ni-chelate column chromatography [5, 10]. Briefly, the seed culture (10 mL) in LB broth was transferred to 400 mL of LB broth for 3 min. The soluble fraction (5 μL) corresponded to 10 μL of the cultured cells was applied on a lane. F, purified nanoKAZ (nK), QL-nanoKAZ (QL-nK), and SNH-nanoKAZ (SNH-nK) from E. coli cells using a Ni-chelate column. Each luciferase (10 μg protein) was applied. M, molecular weight markers. The numbers on the left margin represent the molecular weight of marker proteins (TEFCO): Phosphorylase b (97.4 kDa), bovine serum albumin (69.0 kDa), glutamic dehydrogenase (55.0 kDa), lactic dehydrogenase (36.5 kDa), carbonic anhydrase (29.0 kDa), trypsin inhibitor (20.1 kDa), and lysozyme (14.3 kDa).

https://doi.org/10.1371/journal.pone.0272992.g003

Fig 3. SDS-PAGE analyses of the soluble fractions of the reverse mutants expressed in E. coli cells using a pCold-ZZ-P-X vector (A-E) and the purified nanoKAZ, QL-nanoKAZ, and SNH-nanoKAZ from E. coli cells (F). A-E, the soluble fractions of mutant proteins obtained from E. coli cells by centrifugation at 12,000 × g for 3 min. Panels A-E correspond to those in Fig 2. The soluble fraction (5 μL) corresponded to 10 μL of the cultured cells was applied on a lane. F, purified nanoKAZ (nK), QL-nanoKAZ (QL-nK), and SNH-nanoKAZ (SNH-nK) from E. coli cells using a Ni-chelate column. Each luciferase (10 μg protein) was applied. M, molecular weight markers. The numbers on the left margin represent the molecular weight of marker proteins (TEFCO): Phosphorylase b (97.4 kDa), bovine serum albumin (69.0 kDa), glutamic dehydrogenase (55.0 kDa), lactic dehydrogenase (36.5 kDa), carbonic anhydrase (29.0 kDa), trypsin inhibitor (20.1 kDa), and lysozyme (14.3 kDa).
containing 100 μL of antifoam (Disform CE475, NOF Co., Tokyo, Japan) in a 2-L Sakaguchi flask and cultured with reciprocal shaking (130 rpm) at 37˚C for 3 h. The absorbance at 660 nm measured by TAITEC model mini photo 518R was 0.97 and reached 1.22 after 18 h at 15˚C by the addition of IPTG to a final concentration of 0.2 mM. The harvested cells from 800 mL of culture medium (wet weight, 5.1 g) by using a Hitachi model CR20GIII high-speed refrigerated centrifuge (Tokyo, Japan) at 5,000 rpm for 5 min were suspended in 60 mL of 50 mM Tris-HCl (pH 7.6) and disrupted by sonication three times for 3 min in an ice-water bath. The soluble fractions obtained by centrifugation at 10,000 rpm for 20 min were applied on a Ni-chelate column (ø 2.5 × 5 cm) at room temperature. After washing with 200 mL of 50 mM Tris-HCl (pH 7.6), the fractions of QL-nanoKAZ containing 154.2 mg proteins were obtained by eluting with 0.1 M imidazole (Wako Pure Chemicals) in 50 mM Tris-HCl (pH 7.6). For further purification, a portion of the eluted QL-nanoKAZ fractions (98.8 mg protein) from the 1st Ni-chelate column was diluted to 200 mL with 50 mM Tris-HCl (pH 7.6) containing 2 M NaCl and was applied on the 2nd Ni-chelate column (ø 1.5 × 6 cm) and the proteins were eluted with 0.1 M imidazole. The highly purified QL-nanoKAZ (91.8 mg protein) was obtained (Fig 3F and S2 Table) and used as a protein source for crystal structure analysis.

For purification of SNH-nanoKAZ, the EcoRI-XbaI fragment of for SNH-nanoKAZ gene was chemically synthesized (Eurofine Genomics) and was replaced with the EcoRI-XbaI fragment of nanoKAZ gene in pCold-dnKAZ [10] to give an expression vector, pCold-SNH-nanoKAZ. The purification procedures were essentially the same as that of QL-nanoKAZ, and the yield was 135.6 mg protein from 800 mL of cultured cells (Fig 3F).

Expression of luciferase genes in mammalian cells

For the secretory expression of wild KAZ mutants in mammalian cells, a pcDNA3-GLsp vector that is a derivative of pcDNA3 (Invitrogen, Carlsbad, CA) having the signal peptide sequence of GLase for secretion was used, as previously described [5]. The expression vectors were constructed as follows. The fragment of the mutated KAZ gene obtained by PCR procedures was inserted into the HindIII-XbaI sites of pcDNA3 or the EcoRI/XbaI site of pcDNA3-GLsp [5] to give pcDNA3-dnKAZ, pcDNA3-AQQL-nK (this work), and pcDNA3-QL-nK (this work) for expression in the cytoplasm, or pcDNA3-GLsp-dnKAZ [6], pcDNA3-GLsp-QL-nK (this work), pcDNA3-GLsp-SNH-nK (this work), and pcDNA3-GLsp-EpGLuc [25,26] for secretory expression. These vectors had the identical nucleotide sequence between the promoter and the initial methionine codon in the same vector [25,26]. For transient expression in Chinese hamster ovary-K1 (CHO-K1) cells, CHO-K1 cells (1 × 10⁵ cells) cultured in 2 mL of Ham’s F-12 medium (Wako Pure Chemicals) containing 10% (v/v) heat-inactivated fetal calf serum (Bio-west, France) without antibiotics were seeded in a 6-well plate (n = 4) at 37˚C in a humidified atmosphere of 5% CO₂ for 24 h. For transfection, the mixture of the expression vector (1 μg) and FuGENE HD (3 μL, Promega) in 100 μL of serum-free Ham’s F-12 medium was added to the cells. After further incubation for 24 h, the culture medium was recovered and the cells were washed three times with 2 mL of PBS (D-PBS (–), Wako Pure Chemicals), and then lysed in 400 μL of lysis buffer (2 mM EDTA, 1% Triton-X 100 (Sigma) and 10% glycerol (Wako Pure Chemicals) in PBS), for 15 min at room temperature (24–26˚C). The culture medium and cell extracts (2 μL) were used for luminescent assays (n = 2) [25,26].

Assay for luminescence activity

The luminescence activity was determined using an ATTO (Tokyo, Japan) AB2200 luminometer (Ver.2.07, rev4.21) in the presence of a 0.23% neutral density filter (determined by using a laser at 544 nm) or an ATTO AB2270 luminometer with an F2-cut filter (HOYA, R62).
Under these measurement conditions, the luminescence intensity of AB2270 showed 1.8-fold higher than that of AB2200 using aequorin as a light standard [27].

The reaction mixture (100 μL) contained CTZ or CTZ analog (1 μg/μL dissolved in ethanol) in 30 mM Tris-HCl (pH 7.6)–10 mM EDTA, and the luminescence reaction was initiated by the addition of 1–5 μL of luciferase solutions. The luminescence intensity was recorded in 0.1 s-intervals for 10–60 s using an AB2200 or AB 2270 luminometer. The maximum intensity of luminescence (I_{max}) and the integrated luminescence intensity (Int.) were shown as relative light units (rlu).

**Bioluminescence spectral analysis**

Bioluminescence spectra were measured with a fluorescence spectrophotometer FP-6500 (Jasco, Tokyo, Japan) at 24˚C with the excitation light source turned off (emission bandwidth, 20 nm; sensitivity, medium; response, 0.5 s; scan speed, 1000 nm/min). The corrected bioluminescence spectra were obtained by the manufacturer’s protocol. The reaction mixture (1 mL) in a quartz cuvette contained 5 μg of CTZ or CTZ analog (dissolved in 5 μL of ethanol) in 30 mM Tris-HCl (pH 7.6)–10 mM EDTA, and the luminescence reaction was initiated by adding 5 μL of the purified luciferase (1.0 μg protein) to the reaction mixture.

**Protein analysis**

SDS-PAGE analysis was carried out under reducing conditions using a 12% separation gel (TEFCO, Tokyo, Japan) and the gel was stained with a colloidal CBB staining kit (TEFCO). The protein concentrations of nanoKAZ, QL-nanoKAZ, SNH-nanoKAZ, GLase, and aequorin were determined by amino acid composition analysis, as previously described [27], and other luciferases were determined by the dye-binding method using a commercially available kit (Bio-Rad, Richmond, CA, USA) and bovine serum albumin as a standard (Pierce, Rockford, IL, USA).

**HPLC analysis of the reaction products of CTZ by the CTZ-utilizing luciferase**

The reaction mixture containing each CTZ-utilizing luciferase (5 μg/5 μL) and CTZ (2 μg = 473 pmol/μL dissolved in ethanol) in 100 μL of 50 mM Tris-HCl (pH 7.6) was incubated at 25˚C for 2 h and then was added to 100 μL of 6 M guanidine-HCl in H_2O (pH 7.3) (Wako Pure Chemicals), and was extracted with 500 μL of diethyl ether using a vortex mixer for 15 s. After centrifugation at 10,000 rpm for 3 min at room temperature, 450 μL of ether layer was recovered and was dried down in vacuo. The resultant residues were dissolved in 100 μL of ethanol, showing purple-blue fluorescence under a 365 nm lamp, and 10 μL of the solution was subjected to HPLC analysis for CTZ, CTMD, CTM, CTO, and dCTZ [19,28]. An Agilent (CA, USA) 1200 series HPLC system was used under the following conditions: column, Wakosil 5C4 (ø4.6 mm × 250 mm); eluting solvent, CH_3CN/H_2O containing 0.1% trifluoroacetic acid; gradient elution, 40% CH_3CN for 10 min, 40–50% CH_3CN for 20 min, 50–80% CH_3CN for 10 min, and 80% CH_3CN for 10 min; flow rate, 0.5 mL/min; column temperature, 25˚C; and detector, 225, 280, 330 and 450 nm using a diode array detector.

**Crystallization, data collection, and structure determination**

The eluted fractions of QL-nanoKAZ (50 mg protein) from the Ni-chelate column were diluted twice with the buffer (20 mM Tris-HCl (pH 8.5) and 2 mM DTT) and then loaded on a HiTarp Q HP column (Cytiva, MA, USA). The fractions containing QL-nanoKAZ were eluted
at 200 mM NaCl by a linear gradient from 50 mM to 400 mM of NaCl and concentrated by an Amicon Ultra centrifugal filter unit (MWCO 10,000, Merck-Millipore, Billerica, MA, USA), and separated by a HiLoad 16/60 Superdex 75 column (Cytiva) equilibrated with 20 mM Tris-HCl (pH 8.0) containing 150 mM NaCl and 2 mM DTT. The fractions of QL-nanoKAZ were concentrated to a concentration of 20 mg/mL by a centrifugal filter unit and stored at –80°C. The crystallization was performed by the method of sitting drop vapor diffusion. The crystals were grown in a mixture of 0.2 μL of QL-nanoKAZ and 0.2 μL of the precipitant solution (100 mM MES (pH 6.5) and 1.9 M MgSO_4) at 20°C. After a few days of incubation for equilibration against the precipitant solution, the crystals with dimensions of 250 μm × 250 μm × 20 μm were obtained (S1 Fig). The crystals were cryoprotected in the reservoir solution supplemented with 25% (v/v) glycerol before flash-cooling in liquid nitrogen. An X-ray diffraction dataset was collected to 1.70 Å at a wavelength of 1.0 Å on beamline BL26B2 at SPring-8 [29]. The diffraction data were processed using the XDS programs [30] and the structure was solved by molecular replacement using the Phaser program [31] from the PHENIX programs [32], with the nanoKAZ coordinates (PDB ID: 5B0U) as the search model. The structural model was built into the electron density map using COOT [33] and refined using the PHENIX program. All structure figures were prepared using PyMOL (http://pymol.sourceforge.net/).

**Results and discussion**

**Soluble expression of nanoKAZ mutants in bacterial cells**

Previous studies have reported that wild KAZ and its mutated proteins were mainly expressed as inclusion bodies in *E. coli* cells [3,4]. To express soluble KAZ mutants in *E. coli* cells [5–7], the mutated proteins were expressed as the fusion protein with the ZZ domain of staphylococcal protein A using the cold-induced expression vector, pCold-ZZ-P-X [24]. The chimeric genes between wild KAZ and nanoKAZ (Fig 2A) and the reverse mutated genes of nanoKAZ were prepared using PCR procedures (Fig 2B–2E), and the mutated proteins fused to the ZZ domain were all successfully expressed as soluble form in *E. coli* cells.

The soluble fraction obtained by centrifugation was analyzed by SDS-PAGE (Fig 3A–3E), suggesting that the expression levels of each protein were not significantly different among them under the same culture conditions. Thus, the soluble fractions were used as luciferase sources for the luminescence assay without further purification. The luminescence activities of *I*<sub>max</sub> and *Int*. 60 s were used as tentative indicators for substrate specificity.

**Substrate selectivity of chimera mutants and reverse mutants**

To characterize the substrate specificities of the wK/nK chimera consisting of 1–82 aa of wild KAZ (wK) and 83–169 aa of nanoKAZ (nK) and the nK/wK chimera consisting of 1–82 aa of nK and 83–169 aa of wK, these were expressed in *E. coli* cells and the soluble fraction was used for assays (Fig 2A). As shown in Table 1A, the soluble fraction of nanoKAZ fused to the ZZ domain showed the following luminescence activities of *I*<sub>max</sub>: CTZ (1.0), h-CTZ (17.4), 6h-CTZ (0.7), bis-CTZ (13.7), f-CTZ (15.3), 6h-f-CTZ (10.5), and FMZ (6.3), similar to that of purified nanoKAZ protein [5].

Interestingly, the wK/nK chimera could use CTZ as the preferred substrate and showed 8.6-fold higher activity than nanoKAZ (Table 1A). By contrast, the luminescence activity of the nK/wK chimera with CTZ was decreased significantly (Table 1A). Furthermore, the single reverse mutations of wK/nK at the nanoKAZ region (83–169 aa) with V90I (wK/nK-90I), E115P (wK/nK-115P), K124Q (wK/nK-124Q), I138Y (wK/nK-138Y), or R166N (wK/nK-166N) (Fig 2B) also failed to stimulate the luminescence activity with CTZ (Table 1B).
Unexpectedly, wK/nK-124Q could only use 6h-CTZ efficiently, similar to CTZ. Thus, the amino-terminal region (1–82 aa) of wild KAZ might contribute to the stimulation of luminescence activity with CTZ. From this result, we focused on the amino-terminal region of wild KAZ (wK: 1–82 aa) and produced three reverse mutants of nK-AQQL (E4A, R11Q, L18Q, and V27L), nK-KVA (R43K, I44V, and I54A), and nK-FLM (D68F, Q72L, and K75M) (Fig 2C).

Among them, nK-AQQL showed the highest luminescence with 19.3-fold more activity than nanoKAZ with CTZ (Table 1C). Thus, the amino-terminal region of wild KAZ (1–27 aa) might directly or indirectly affect its substrate recognition for CTZ.

Reverse mutants of QL-nanoKAZ show high selective luminescence activity with CTZ

To elucidate the specific amino residue for luminescence stimulation with CTZ among four amino acid residues (E4A, R11Q, L18Q, and V27L) in nK-AQQL, four single-reverse mutants of nK-AQQL (E4A, R11Q, L18Q, and V27L), nK-KVA (R43K, I44V, and I54A), and nK-FLM (D68F, Q72L, and K75M) (Fig 2C). Among them, nK-AQQL showed the highest luminescence with 19.3-fold more activity than nanoKAZ with CTZ (Table 1C). Thus, the amino-terminal region of wild KAZ (1–27 aa) might directly or indirectly affect its substrate recognition for CTZ.

### Table 1. Luminescence activities of chimeric proteins among wild KAZ, nanoKAZ, and their reverse mutants of nanoKAZ using coelenterazine (CTZ) and CTZ analogs as a substrate.

| nanoKAZ mutant \ (ZZ domain fused protein) | CTZ | h-CTZ | 6h-CTZ | bis-CTZ | f-CTZ | 6h-f-CTZ | FMZ |
|-------------------------------------------|-----|-------|--------|---------|-------|---------|-----|
| A. nanoKAZ (nK)                           | 1.0 | 1.0   | 17.4   | (12.9)  | 0.7   | (0.6)   | 13.7 | (13.5)  | 15.3 | (12.8) | 10.5 | (9.5)  | 6.3  | (6.0)  |
| KAZ (wK)                                  | 0.13| (0.14)| 0.16   | (0.13)  | 0.01  | (0.02)  | 0.06 | (0.10)  | 0.13 | (0.12) | 0.04 | (0.06) | 0.03 | (0.05) |
| wK/nK                                    | 8.6 | (7.9) | 8.6    | (4.6)   | 1.2   | (1.0)   | 4.3  | (3.4)   | 6.4  | (4.5)  | 5.5  | (4.7)  | 3.5  | (4.1)  |
| nK/wK                                    | 0.5 | (0.6) | 5.3    | (4.4)   | 0.2   | (0.2)   | 2.8  | (2.8)   | 4.5  | (3.5)  | 2.3  | (1.5)  | 2.0  | (1.5)  |
| B. wk/nK-90I                              | 4.5 | (5.0) | 5.3    | (3.1)   | 0.7   | (0.8)   | 3.1  | (2.9)   | 4.2  | (3.0)  | 3.1  | (3.2)  | 2.3  | (2.1)  |
| wk/nK-115P                                | 4.1 | (3.7) | 3.6    | (2.4)   | 0.8   | (0.9)   | 2.4  | (2.7)   | 2.9  | (2.0)  | 1.8  | (1.5)  | 1.7  | (1.6)  |
| wk/nK-124Q                                | 4.5 | (4.5) | 9.3    | (5.8)   | 6.2   | (6.1)   | 4.9  | (4.7)   | 8.6  | (3.6)  | 5.4  | (4.9)  | 2.4  | (1.5)  |
| wk/nK-138Y                                | 1.1 | (1.2) | 4.6    | (3.1)   | 0.2   | (0.4)   | 2.4  | (2.3)   | 3.9  | (2.5)  | 2.3  | (1.4)  | 1.5  | (1.3)  |
| wk/nK-166N                                | 4.3 | (5.0) | 5.7    | (3.9)   | 0.6   | (0.9)   | 2.3  | (2.5)   | 5.1  | (3.8)  | 1.8  | (1.2)  | 2.2  | (1.7)  |
| C. nanoKAZ (nK)                           | 1.0 | (1.0) | 14.2   | (7.4)   | 0.6   | (0.4)   | 9.0  | (6.3)   | 20.2 | (10.0) | 7.9  | (4.6)  | 4.8  | (3.7)  |
| nK-AQQL                                   | 19.3| (11.6)| 28.9   | (10.5)  | 5.4   | (3.9)   | 4.8  | (4.9)   | 21.0 | (8.0)  | 4.6  | (5.0)  | 2.3  | (2.6)  |
| nK-KVA                                    | 0.6 | (0.6) | 9.1    | (4.7)   | 0.1   | (3.9)   | 11.1 | (7.5)   | 17.4 | (7.2)  | 11.9 | (7.7)  | 5.4  | (3.6)  |
| nK-FLM                                    | 0.3 | (0.3) | 9.5    | (6.5)   | 0.2   | (0.1)   | 5.7  | (3.2)   | 10.9 | (5.9)  | 9.0  | (4.7)  | 3.0  | (2.3)  |

a The mutated protein fused to ZZ domain was expressed in E. coli cells using a pCold-ZZ-P-X vector [24].

b The luminescence activity (n = 2) was determined using an AB2200 luminometer with a 0.23% neutral density filter and shown as the relative intensity to that of nanoKAZ (nK) with CTZ. The experiment C was performed separately from the experiments A and B.

c Integration for 60 s in 0.1 s-intervals.

d I_{max} = 2.8 \times 10^5 \text{ rlu/0.1 s}.

e Int. 60 s = 8.3 \times 10^7 \text{ rlu/60 s}.

f I_{max} = 1.2 \times 10^4 \text{ rlu/0.1 s}.

g Int. 60 s = 5.0 \times 10^6 \text{ rlu/60 s}.

h Vertical arrows (\u201c\u201d) indicate over 50% increase of both I_{max} and Int. 60 s values against nanoKAZ with each CTZ analog, respectively.

https://doi.org/10.1371/journal.pone.0272992.t001
Table 2. Luminescence activities of reverse mutants of nanoKAZ using coelenterazine (CTZ) and CTZ analogs as a substrate.

| nanoKAZ mutant * (ZZ domain fused protein) | Relative luminescence activity b, I_max (Int. 60 s) |
|-------------------------------------------|-----------------------------------------------|
|                                           | CTZ   | h-CTZ | 6h-CTZ | bis-CTZ | f-CTZ |
| D. nanoKAZ (nK)                          | 1.0   | 7.8   | 0.9    | 6.3     | 8.3   |
| nK-4A                                    | 1.0   | 7.5   | 1.0    | 6.1     | 7.7   |
| nK-11Q                                   | 1.3   | 7.2   | 1.1    | 6.6     | 7.4   |
| nK-18Q                                   | 2.9   | 7.0   | 0.9    | 4.1     | 8.6   |
| nK-27L                                   | 4.7   | 7.9   | 3.3    | 5.4     | 8.6   |
| E. nK-4A11Q                              | 1.2   | 7.4   | 0.9    | 7.1     | 7.6   |
| nK-4A18Q                                 | 3.1   | 8.7   | 1.0    | 4.5     | 9.1   |
| nK-4A27L                                 | 4.6   | 7.0   | 3.0    | 5.5     | 8.6   |
| nK-11Q18L                                | 4.2   | 8.7   | 1.6    | 5.1     | 9.2   |
| nK-11Q27L                                | 5.6   | 8.2   | 3.9    | 5.4     | 9.3   |
| nK-18Q27L                                | 12.3  | 7.9   | 3.0    | 2.7     | 6.4   |

a The mutated protein fused to ZZ domain was expressed in E. coli cells using a pCold-ZZ-P-X vector [24].
b The luminescence activity (n = 2) was determined using an AB2200 luminometer with a 0.23% neutral density filter and shown as the relative intensity to that of nanoKAZ (nK) with CTZ.
c Integration for 60 s in 0.1 s-intervals.
d 1.8 × 10^5 rlu/0.1 s.
e 6.1 × 10^7 rlu/60 s.
‡ Vertical arrows (‡) indicate over 50% increase of both I_max and Int. 60 s values against nanoKAZ with each CTZ analog.

124Q (Table 2E), though the reason for the high luminescence activity with 6h-CTZ was unclear. A schematic representation of the relationships between the reverse mutants and their luminescence activities with CTZ and bis-CTZ are summarized in Fig 2, based on the results shown in Tables 1 and 2.

Expression and purification of nanoKAZ, QL-nanoKAZ, and SNH-nanoKAZ from bacterial cells

To compare the luminescence properties of QL-nanoKAZ with those of nanoKAZ, SNH-nanoKAZ, and native OpLase, we expressed nanoKAZ, QL-nanoKAZ, and SNH-nanoKAZ as soluble proteins without the ZZ domain and highly purified them using Ni-chelate column chromatography (Fig 3F). It has been reported that SNH-nanoKAZ (teLuc) is a mutant of nanoKAZ with three amino acid substitutions (D19S, D85N, and C169H) and showed approximately 2-fold higher I_max value than FMZ using diphenylterazine (DTZ) (Fig 1B) with a red-shifted emission peak at 502 nm [15]. The protein concentrations of the purified luciferases were determined by amino acid composition analysis [27] and used for normalization of the luminescence activities and estimation of the luciferase concentration expressed in the mammalian cells.

The luminescence kinetics and emission spectrum of QL-nanoKAZ were determined using CTZ and its four analogs. QL-nanoKAZ with CTZ showed the highest luminescence activity with slow decay kinetics (Fig 4A). The emission peaks of QL-nanoKAZ with CTZ and its analogs were around 458 nm, similar to native OpLase [4] and nanoKAZ [5] (Fig 4B). The linearity of luminescence activity for QL-nanoKAZ under various concentrations of CTZ was determined (Fig 4C) and the relative values of I_max and Int. 30 s were normalized using recombinant aequorin as a light standard (Table 3). Among the CTZ-utilizing luciferases, GLase is known to have the highest I_max value with fast decay kinetics [21,27]. The I_max value of QL-nanoKAZ with CTZ showed a similar order to that of GLase with more than 80-fold higher
Fig 4. Luminescence properties of QL-nanoKAZ. A. Luminescence kinetics of QL-nanoKAZ with CTZ and its analogs as substrates. B. Normalized luminescence spectra of QL-nanoKAZ with CTZ and its analogs, based on the luminescence intensity of QL-nanoKAZ with CTZ. C. Linearity of luminescence intensity ($I_{max}$) of QL-nanoKAZ with CTZ, in comparison with nanoKAZ, SNH-nanoKAZ, GLase, and aequorin at the protein concentrations of 0.3 pg to 3 ng ($n = 6$). Solid and dashed lines represent blank + 3 SD for aequorin and the CTZ-utilizing luciferases, respectively.

https://doi.org/10.1371/journal.pone.0272992.g004

The luminescence activity of nanoKAZ, and the luminescence kinetics was the slow decay pattern with a 2.6-fold higher value of $I_{max}$ at 30 s than that of GLase (Table 3). Thus, QL-nanoKAZ is a potential candidate for the reporter protein in the glow luminescence assay system.

Expression of QL-nanoKAZ in mammalian cells

OpLase is a secretory protein, but the catalytic component of wild KAZ could not be secreted from mammalian cells using its own signal peptide sequence [4,8] or other signal peptide sequences such that from GLase [8]. However, the signal peptide sequence for GLase (GLsp) has been successfully used for the secretion of nanoKAZ in CHO-K1 cells [5]. To evaluate QL-nanoKAZ as a reporter protein in mammalian cells, it was transiently expressed in CHO-K1 cells. The amount of QL-nanoKAZ secreted into the culture medium was similar to nanoKAZ and GLase (Table 4).

As previously reported, nanoKAZ could be secreted into the culture medium even without a signal peptide sequence by the unknown mechanism [8]. Approximately 10% of nanoKAZ and QL-nanoKAZ without the signal peptide sequence was secreted into the culture medium [8], contrary to the report for nanoLuc by Hall et al. [9] (Table 5). Thus, QL-nanoKAZ with CTZ can be used as a reporter protein in the cytoplasm, similar to nanoKAZ/nanoLuc with bis-CTZ and h-CTZ [5]. However, based on the slow decay luminescence pattern of QL-nanoKAZ (Fig 4A), it was not suitable for real-time imaging of protein secretion from mammalian cells like GLase (unpublished results) [34,35].

Luminescent products of CTZ catalyzed by CTZ-utilizing luciferases

In the oxidation process of CTZ with $O_2$ by luciferase, 2-peroxycoelenterazine (CTZ-OOH) might be an intermediate, from which CTMD is produced with light emission (Fig 1A). To

Table 3. Comparison of luminescence activity of QL-nanoKAZ with other CTZ-utilizing luciferases using aequorin as a light standard.

| Photoprotein or luciferases | Number of amino acids (Average mass value) | Relative luminescence intensity $^a$ |
|----------------------------|-------------------------------------------|-----------------------------------|
|                            | $I_{max}$ | $Int. 30\ s$ |
| Aequorin                   | 191 (21,632.20) | 1.0$^b$ | 1.0$^c$ |
| nanoKAZ (= nanoLuc)        | 191 (21,491.56) | 0.12 | 3.4 |
| QL-nanoKAZ                 | 191 (21,520.55) | 10.0 | 240 |
| SNH-nanoKAZ (= teLuc)      | 191 (21,496.56) | 0.53 | 15.0 |
| GLase                      | 174 (18,992.87) | 12.3 | 92.0 |

$^a$ Each purified recombinant luciferase and aequorin were dissolved in 0.1% bovine serum albumin (Sigma) in 50 mM Tris–HCl (pH 7.6)–10 mM EDTA. The luminescence reaction was initiated by adding 3 μL of each luciferase (300 pg) to 100 μL of PBS (Sigma) containing 1 μg of CTZ (1 μg/μL dissolved in ethanol). The luminescence activity ($n = 6$) was determined for 30 s using an AB2270 luminometer with an F2-cut filter. For aequorin assay, 100 μL of 50 mM CaCl$_2$ in H$_2$O was injected into 3 μL of aequorin (300 pg).

$^b$ 2.1 × $10^7$ rlu/μg aequorin.

$^c$ 2.0 × $10^8$ rlu/μg aequorin.

https://doi.org/10.1371/journal.pone.0272992.t003
identify the luminescent products of CTZ with the CTZ-utilizing luciferases, CTZ was incubated with each luciferase for 2 h and the products were analyzed by HPLC (Fig 5). The major and minor products from CTZ catalyzed by luciferases were CTMD and CTM, respectively. This was similar to the result obtained from CTZ-OOH in the Ca\textsuperscript{2+}-triggered luminescence reaction of aequorin [36]. Recently, we investigated the degradation products from ((S)-2-peroxycoelenterazine ((S)-CTZ-OOH) in aequorin under protein denaturing conditions and the major product was identified as CTM, but not CTMD, without light emission. In addition, we confirmed that CTMD was not hydrolyzed to CTM in aqueous solutions [36]. Thus, CTZ-OOH might be an intermediate in the luminescence reaction of CTZ catalyzed by these CTZ-utilizing luciferases.

The efficiency of CTMD formation might be correlated with the luminescence activity of luciferases. Interestingly, even though CTZ is not a suitable substrate in nanoKAZ [5,9], CTZ was completely consumed and converted to CTMD and CTM with 63% and 37% in 2 h, respectively (Table 6). As we recently reported, the products after incubation of CTZ (473 pmol) in 50 mM Tris-HCl (pH 7.6) at 25˚C for 2 h in the absence of luciferase were CTZ (149 pmol), CTMD (68 pmol), CTM (65 pmol), dCTZ (90 pmol) and an unknown product (Table 6) [19]. Because the formation of dCTZ was not detected in the reaction mixtures of CTZ with nanoKAZ and other luciferases, the CTM and CTMD formation from CTZ by

| Expression -type | Expression vector | Relative luminescence intensity (I\textsubscript{max}, %) \textsuperscript{a} |
|------------------|--------------------|-----------------------------------|
|                  |                    | CTZ Medium | Cell extracts | bis-CTZ Medium | Cell extracts |
| Secretion        | pcDNA3-GLsp-dnKAZ  | 1.8        | 0.5          | 20.7           | 8.2          |
|                  | pcDNA3-GLsp-QL-nK  | 100 \textsuperscript{b} | 24.7        | 16.8           | 7.3          |
| Cytoplasm        | pcDNA3-dnKAZ       | 1.2        | 16.2         | 16.1           | 235          |
|                  | pcDNA3-AQQL-nK     | 28.7       | 353          | 4.0            | 74.6         |
|                  | pcDNA3-QL-nK       | 21.1       | 241          | 3.5            | 74.4         |

\textsuperscript{a} The luminescence activity (n = 2) was determined using an AB2270 luminometer with an F2-cut filter for 10 s in 0.1 s-intervals.

\textsuperscript{b} 17.6 \times 10^6 rlu/6-wells (n = 4).
Reverse mutants of nanoKAZ with coelenterazine as preferred substrate

- a) Authentic
- b) nanoKAZ (= nanoLuc)
- c) QL-nanoKAZ
- d) SNH-nanoKAZ (= TeLuc)
- e) GLase
- f) RLase
- g) RLase-547

Abs (mAU) vs. Time (min)
nanoKAZ could be an enzymatic oxidation process. The low luminescence activity of nanoKAZ might be explained by that CTZ-OOH could not properly stabilized in the nanoKAZ molecule during the luminescence reaction and partially decomposes into CTM and CTMD without light emission [36].

Substrate specificities of nanoKAZ, QL-nanoKAZ, SNH-nanoKAZ, and native OpLase for CTZ analogs

As previously reported, native OpLase showed broad substrate specificity [11], and the catalytic component of 19 kDa protein (wild KAZ) in OpLase also showed similar substrate specificity [4,13]. As summarized in Table 7, nanoKAZ and SNH-nanoKAZ showed lower luminescence activity with CTZ, but other profiles of substrate specificity were similar to those of OpLase and wild KAZ. By contrast, QL-nanoKAZ could use CTZ and h-CTZ as the preferred substrates, similar to OpLase [11] and wild KAZ [13]. The $I_{\text{max}}$ value of QL-nanoKAZ with CTZ was 2.6- and 5.3-folds higher than that of nanoKAZ with bis-CTZ and FMZ, respectively (Table 7). Furthermore, QL-nanoKAZ with all C2-modified CTZ analogs possessing the hydroxy moiety (-OH) at the C6 benzyl group retained higher luminescence activity than those of nanoKAZ and SNH-nanoKAZ. Among these mutants, similar luminescence activities were observed for n-CTZ and hcp-CTZ, suggesting that the C2- and C8-groups of CTZ might not be essential for binding to these luciferases (Table 7). In QL-nanoKAZ, stabilization of the hydroxy moiety at the C6-benzyl group of CTZ with specific amino acid residue(s) in the protein might be crucial to stimulate the luminescence activity with CTZ. In addition, the amino acid residues that interact with the C3-carbonyl group of the imidazopyrazinone structure also might be required to stabilize CTZ analogs lacking the hydroxy moiety at the C6-benzyl group of CTZ (i.e., bis-CTZ, 6h-CTZ, and FMZ).

Table 6. Reaction products of coelenteramine (CTM) and coelenteramide (CTMD) from coelenterazine (CTZ) by incubation of various CTZ-utilizing luciferases by HPLC analysis.

| Luciferase + CTZ (2 μg, 473 pmol) | CTM * (pmol) | CTZ * (pmol) | CTMD * (pmol) | dCTZ * (pmol) | Products recovery from CTZ (%) | % of CTMD b |
|---------------------------------|--------------|--------------|---------------|---------------|--------------------------------|------------|
| nanoKAZ (= nanoLuc)            | 119          | ND           | 201           | ND            | 68                             | 63         |
| QL-nanoKAZ                     | 8            | ND           | 298           | ND            | 65                             | 97         |
| SNH-nanoKAZ (= teLuc)          | 12           | ND           | 321           | ND            | 70                             | 96         |
| Glase                          | 21           | ND           | 371           | ND            | 83                             | 95         |
| RLase                          | 59           | ND           | 325           | ND            | 81                             | 85         |
| RLase-547                      | 30           | ND           | 276           | ND            | 65                             | 90         |
| without luciferase d            | 65           | 149          | 68            | 90            | 79                             | -          |

* Estimated with the peak area on HPLC chart using authentic CTM, CTZ, CTMD, and dCTZ as standards.

b Calculated with the equation of CTMD/(CTM + CTMD).

* Not detected.

<https://doi.org/10.1371/journal.pone.0272992.t006>
### Table 7. Substrate specificities and luminescence properties for purified QL-nano KAZ, nanoKAZ, SNH-nano KAZ, and native *Oplophorus* luciferase (OpLase).

| Coelenterazine analogs | QL-nano KAZ | nanoKAZ | SNH-nano KAZ | OpLase |
|------------------------|-------------|---------|--------------|--------|
|                        | $I_{\text{max}}$ (%) | $\text{Int. 60 s}$ (%) | $\lambda_{\text{max}}$ (nm) | $I_{\text{max}}$ (%) | $\text{Int. 60 s}$ (%) | $\lambda_{\text{max}}$ (nm) | $I_{\text{max}}$ (%) | $\text{Int. 60 s}$ (%) | $\lambda_{\text{max}}$ (nm) | $I_{\text{max}}$ (%) | $\text{Int. 60 s}$ (%) | $\lambda_{\text{max}}$ (nm) |
| CTZ | None | 100 $^a$ | 100 $^b$ | 458 | 74 | 3 | 1 | 457 | 74 | 11 | 14 | 460 | 75 | 100 $^c$ | 100 $^d$ |
| $\text{bis}$ | 2: -CH$_2$C$_6$H$_5$ 6: -CH$_3$ | 16 | 14 | 451 | 74 | 38 | 48 | 451 | 74 | 38 | 40 | 454 | 75 | 38 | 44 |
| $h$ | 2: -CH$_2$C$_6$H$_5$ 6: -CH$_3$ | 86 | 36 | 457 | 72 | 64 | 49 | 458 | 72 | 40 | 20 | 460 | 77 | 73 | 44 |
| $6h$ | 6: -C$_6$H$_5$ | 18 | 20 | 451 | 75 | 2 | 3 | 454 | 75 | 8 | 8 | 454 | 75 | 4 | 4 |
| FMZ | 2: 2-furanyl methyl 6: -C$_6$H$_5$ | 7 | 9 | 451 | 73 | 19 | 26 | 451 | 70 | 17 | 23 | 454 | 73 | 16 | 18 |
| $\text{hcp}$ | 2: -CH$_2$C$_6$H$_5$ 8: -CH$_2$C$_6$H$_5$(c) | 26 | 14 | 446 | 70 | 10 | 8 | 449 | 70 | 19 | 12 | 447 | 70 | 24 | 19 |
| $\text{ameh}$ | 2: 1-phenylethyl | 10 | 6 | 453 | 74 | 1 | 1 | 464 | 77 | 3 | 3 | 460 | 75 | 3 | 3 |
| $f$ | 2: -CH$_2$C$_6$H$_5$F(p) | 64 | 21 | 453 | 70 | 71 | 52 | 453 | 70 | 45 | 30 | 454 | 69 | 39 | 37 |
| $3iso$ | 2: -CH$_2$C$_6$H$_5$OH(m) | 53 | 40 | 457 | 73 | 6 | 7 | 460 | 74 | 14 | 17 | 459 | 73 | 23 | 24 |
| $\text{meo}$ | 2: -CH$_2$C$_6$H$_5$OCH$_3$(p) | 53 | 25 | 455 | 72 | 31 | 26 | 456 | 73 | 23 | 19 | 458 | 73 | 32 | 27 |
| $\text{3meo}$ | 2: -CH$_2$C$_6$H$_5$OCH$_3$(m) | 84 | 34 | 457 | 72 | 45 | 37 | 457 | 71 | 37 | 28 | 460 | 72 | 26 | 26 |
| $\text{cf3}$ | 2: -CH$_2$C$_6$H$_5$CF$_3$(p) | 37 | 17 | 454 | 73 | 19 | 11 | 454 | 71 | 20 | 14 | 455 | 73 | 7 | 7 |
| $i$ | 2: -CH$_2$C$_6$H$_5$I(p) | 24 | 11 | 453 | 72 | 11 | 6 | 460 | 75 | 11 | 7 | 457 | 74 | 7 | 6 |
| $\text{me}$ | 2: -CH$_2$C$_6$H$_5$CH$_3$(p) | 65 | 26 | 457 | 74 | 24 | 18 | 458 | 75 | 21 | 15 | 461 | 73 | 20 | 17 |
| $\text{et}$ | 2: -CH$_2$C$_6$H$_5$CH$_3$(p) | 40 | 14 | 457 | 72 | 18 | 10 | 457 | 73 | 15 | 11 | 460 | 74 | 13 | 9 |
| $\text{3me}$ | 2: -CH$_2$C$_6$H$_5$CH$_3$(m) | 49 | 21 | 455 | 73 | 44 | 35 | 457 | 71 | 26 | 21 | 460 | 72 | 48 | 38 |
| $n$ | 2: 2-naphthylmethyl | 17 | 12 | 451 | 70 | 13 | 7 | 453 | 71 | 12 | 9 | 455 | 72 | 11 | 6 |

The assay conditions are as follows: The luminescence reaction was initiated by adding 1 µg of CTZ analogs (dissolved in ethanol) to 100 µL of 30 mM Tris-Cl (pH 7.6)–10 mM EDTA containing 3 µL of 15 ng protein (QL-nano KAZ, nanoKAZ, or SNH-nano KAZ) and 270 ng of OpLase. The luminescence activity ($n = 3$) was determined using an AB2270 luminometer with an F2-cut filter.

- $^a$ 4.9 × 10$^4$ rlu/0.1 s
- $^b$ 2.0 × 10$^4$ rlu/60 s
- $^c$ 1.8 × 10$^4$ rlu/0.1 s
- $^d$ 8.6 × 10$^4$ rlu/60 s

### Effect of deaza-analogs for CTZ and CTZ-OOH on luciferase activity

The chiral deaza-analogs of (S)- and (R)-deaza-CTZ ((S/R)-daCTZ) for CTZ and (S)-2- and (R)-2-hydroxymethyl-deaza-CTZ ((S/R)-HM-daCTZ) for CTZ-OOH (Fig 1C) have been used as inhibitors to investigate the oxidation process of CTZ with O$_2$ in RLase [12] and the regeneration process of the calcium-binding photoprotein, aequorin, from CTZ and O$_2$ [19]. The inhibitory effect on luminescence activity of various CTZ-utilizing luciferases with CTZ was examined in the presence of each deaza-analog (Table 8). As previously reported, RLase was inhibited by (S/R)-daCTZ and by (S)-HM-daCTZ [12]. We proposed that the binding of CTZ to RLase might be a non-stereospecific process, while the following oxidation of CTZ with O$_2$ to CTZ-OOH might be a stereospecific process. Interestingly, the luminescence activities of GLase and RLase-547 were clearly inhibited by (S)-HM-daCTZ and (R)-HM-daCTZ, respectively, suggesting that the addition of O$_2$ to CTZ might be a stereospecific process. Notably, the inhibition stereospecificity of RLase-547 by (R) form of HM-daCTZ was different from that of RLase by (S) form of HM-daCTZ. This result suggested that the addition of O$_2$ to CTZ might be proceeded in the opposite direction between RLase and RLase-547 (Table 8).
Table 8. Inhibition of luminescence activity of CTZ-utilizing luciferases with deaza-coelenterazine (daCTZ) analogs as inhibitors.

| Inhibitors       | OpLase * | nanoKAZ * | QL-nanoKAZ * | SNH-nanoKAZ * | GLase * | RLase * | RLase-547 * | Aequorin * |
|------------------|----------|-----------|--------------|---------------|---------|---------|-------------|-----------|
| None             | 100 b    | 100 b     | 100 b        | 100 b         | 100 b   | 100 b   | 100 b       | 100       |
| (S)-daCTZ        | 2.1      | 26.8      | 0.4          | 21.1          | 0.4     | 0.1     | 0.04        | 5.8       |
| (R)-daCTZ        | 5.1      | 16.6      | 0.4          | 12.7          | 0.5     | 0.2     | 0.1         | 33.4      |
| (S)-HM-daCTZ     | 19.7     | 62.8      | 13.1         | 55.2          | 5.3     | 25.2    | 3.1         | 8.7       |
| (R)-HM-daCTZ     | 33.5     | 60.5      | 18.8         | 54.6          | 23.5    | 1.4     | 27.0        | 92.1      |

* The reaction mixture contained each luciferase in 200 μL of 30 mM Tris-HCl–10 mM EDTA and was incubated with each inhibitor (1 μg/1 μL dissolved in ethanol: (S/R)-daCTZ, 1.2 × 10^{-4} M; (S/R)-HM-daCTZ; 1.2 × 10^{-5} M) for 1 min. Then, the luminescence reaction was initiated by mixing with CTZ (1 μg/1 μL dissolved in ethanol: 1.2 × 10^{-5} M) and the luminescence activity (n = 3) was determined using an AB2270 luminometer with an F2-cut filter. The luciferase concentrations used for assay were as follows: OpLase, 90 ng (4.2 × 10^{-9} M); nanoKAZ, 20 ng (4.7 × 10^{-8} M); QL-nanoKAZ, 5 ng (1.2 × 10^{-9} M); SNH-nanoKAZ, 15 ng (3.5 × 10^{-9} M); GLase, 5 ng (1.3 × 10^{-9} M); RLase, 15 ng (2.0 × 10^{-9} M); RLase-547, 15 ng (2.0 × 10^{-9} M). 

b The I_{max} value without inhibitors is as follows: OpLase, 3.7 × 10^{4} rlu; nanoKAZ, 3.6 × 10^{4} rlu; QL-nanoKAZ, 8.9 × 10^{4} rlu; SNH-nanoKAZ, 1.3 × 10^{5} rlu; GLase, 8.8 × 10^{5} rlu; RLase, 5.9 × 10^{5} rlu; RLase-547, 1.2 × 10^{5} rlu.

* Data obtained from ref. 19.

https://doi.org/10.1371/journal.pone.0272992.1008

Under the same assay conditions, the luminescence activity of QL-nanoKAZ was significantly inhibited by (S/R)-daCTZ, similar to GLase, RLase, and RLase-547. However, nanoKAZ and SNH-nanoKAZ were moderately inhibited by (S/R)-daCTZ. Thus, the binding affinity of CTZ to QL-nanoKAZ might be comparable to that of GLase, RLase, and RLase-547, showing high luminescence activity.

On the other hand, the luminescence activity of OpLase, nanoKAZ, QL-nanoKAZ, and SNH-nanoKAZ were not selectively inhibited by (S)- or (R)-HM-daCTZ, suggesting that the oxidation step of CTZ with O2 by these luciferases might be a non-stereospecific process. However, it is possible that (S/R)-HM-daCTZ binds less efficiency to the catalytic pocket of luciferase due to steric hindrance by the hydroxymethyl group of daCTZ.

Crystal structure of QL-nanoKAZ and substrate specificity for CTZ

Based on the results showing inhibitory effect of deaza-CTZ analogs against QL-nanoKAZ (Table 8), we attempted to determine the complex structure of daCTZ or HM-daCTZ with QL-nanoKAZ, but were unsuccessful. However, in the absence of deaza-CTZ analogs, the structure of QL-nanoKAZ was determined at 1.70 Å resolution (PDB ID: 7VSX). The statistical values of data collection and structure refinement are summarized in Table 9.

The overall structure of QL-nanoKAZ substituted at L18Q and V27L was almost the same as that of nanoKAZ (PDB ID: 5B0U) (Fig 6A). But some structural differences were observed at the α3-helix (29–37 aa), β6-sheet (105–109 aa), and β7-sheet (112–119 aa) (Fig 7). Interestingly, the amino acid residue at Tyr 109 in the β6-sheet showed significant change in position, which might be hydrogen bond formation between the hydroxy group of Tyr 109 and the C6-hydroxy group of CTZ, increasing the affinity with CTZ (Fig 6B).

Recently, we determined the structures of a complex of apoAequorin (apo-protein of aequorin) with (S)-daCTZ (PDB ID: 7EG2) or (S)-HM-daCTZ (PDB ID: 7EG3). The stabilization mechanisms of daCTZ and HM-daCTZ in apoAequorin were identical to that of the complex of apoAequorin and (S)-CTZ-OOH (aequorin: PDB ID: 1EJ3) [19]. Thus, the C6-hydroxy and the C3-carbonyl groups in both CTZ and CTZ-OOH were stabilized by the hydrogen-bonding interactions via three amino acid residues (His 16, Tyr 82, and Trp 86) and His 169, respectively. On the other hand, the Ca^{2+}-triggered Renilla luciferin-binding protein (RLBP) is
a complex of apoRLBP (apoprotein of RLBP) and CTZ [37,38], and apoRLBP can also bind \( h \)-CTZ and bis-CTZ [38]. The crystal structure of RLBP from \( R. \) muelleri containing CTZ has been determined (PDB ID: 2HPS) [39] and CTZ was stabilized with hydrogen-bonding interactions at the C2-hydroxy group with both Tyr 36 and Arg 19, the C6-hydroxy group with Asp 183 and Lys 139 though two H\( \text{H}_2\)O molecules, the C3-carbonyl group with Arg 22, and the N(7) nitrogen with Phe 190. As apoRLBP could stably bind to both \( h \)-CTZ and bis-CTZ to form semi-synthetic RLBP [38], the C3-carbonyl group and the N(7) nitrogen in CTZ might be responsible for the stabilization with apoRLBP without interacting the C2- and C6-hydroxy groups of CTZ. Thus, there are variations in the stabilization pattern of CTZ by the amino acid residues in each protein molecule.

In QL-nanoKAZ, CTZ was the preferred substrate over bis-CTZ and FMZ, which lack the C2- and C6-hydroxy groups of CTZ. When the C2-CTZ analogs were used as a substrate, the decrease in luminescence activity of QL-nanoKAZ was not significant compared to CTZ (Table 6). Thus, the C2-hydroxy group of CTZ might not be essential for binding QL-nanoKAZ, similar to nanoKAZ and SNH-nanoKAZ. Furthermore, hcp-CTZ with a C8 substitution in CTZ could be efficiently used as a substrate by QL-nanoKAZ, nanoKAZ, and SNH-nanoKAZ, indicating that the C8-phenyl group of CTZ was also not required for molecular recognition of CTZ by QL-nanoKAZ. From these results, the high luminescence activity of QL-

### Table 9. Statistics of data collection and structure refinement.

| Data collection and processing |  |
|-------------------------------|---|
| **Beamline**                  | BL26B2 |
| **Space group**               | \( P222 \) |
| **Unit-cell parameter**       |  |
| \( a, b, c (\AA) \)           | 60.8, 76.0, 103.8 |
| \( a, b, c (\AA) \)           | 90.0, 90.0, 90.0 |
| **Wavelength (\AA)**          | 1.000 |
| **Resolution range (\AA)**    | 50–1.70 (1.80–1.70) |
| **Redundancy**                | 7.3 (7.2) |
| **Completeness (%)\(^a\)**    | 98.5 (99.7) |
| **\( R_{sym} \) (%)\(^b\)**  | 7.0 (88.7) |
| **\( I/\sigma(I) \)\(^c\)**  | 15.1 (2.2) |
| **No. monomers/asymmetric unit** | 1 |

| Model refinement |  |
|------------------|---|
| **No. of reflections** | 26752 |
| **No. of protein atoms** | 1355 |
| **No. of water molecules** | 174 |
| **\( R_{work} / R_{free} \) (%)** | 18.2/20.7 |
| **r.m.s.d. for bond length (\AA)\(^d\)** | 0.014 |
| **r.m.s.d. for bond angles (˚)\(^d\)** | 1.2 |

| Residues in the Ramachandran plot |  |
|-----------------------------------|---|
| **Favored region (%)**            | 95.9 |
| **Allowed regions (%)**           | 4.1 |
| **PDB entry**                     | 7VSX |

\(^a\) Statistics for the highest resolution shell are given in parentheses.

\(^b\) \( R_{sym} = (\Sigma_h \Sigma_i |I_{hi} – \langle I \rangle| / \Sigma_h \Sigma_i |I_{hi}|) \) where \( h \) indicates unique reflection indices and \( i \) indicates symmetry equivalent indices.

\(^c\) \( R_{work} = \Sigma |F_{obs} – F_{calc}| / |F_{obs}| \) for all reflections and \( R_{free} \) was calculated using randomly selected reflections (6%).

https://doi.org/10.1371/journal.pone.0272992.t009
nanoKAZ with CTZ might be explained by the high affinity between the C6-hydroxy group of CTZ and QL-nanoKAZ. The reverse mutations at V18Q and V27L in nanoKAZ caused local changes in its structure, resulting in stabilization of CTZ for efficient oxidation with O2.

Although the binding cavity in nanoKAZ for CTZ was not determined, Tyr 109 seems to be the potential amino acid residue that stabilizes the C6-hydroxy group of CTZ with hydrogen-bonding interactions, resulting in efficient oxidation of CTZ.

Conclusions

To investigate the differences in substrate specificities between wild KAZ and nanoKAZ toward CTZ and bis-CTZ, the reverse nanoKAZ mutants substituted with the identical amino acid residue of wild KAZ at the same position were prepared. Among these mutants, a reverse mutant substituted with L18Q and V27L (QL-nanoKAZ) showed the highest luminescence activity with CTZ, and the luminescence properties of QL-nanoKAZ were compared with those of the CTZ-utilizing luciferases including nanoKAZ, Renilla luciferase, and Gaussia luciferase. The results showed that QL-nanoKAZ is an ideal candidate for the reporter protein in various luminescence assay systems. Furthermore, the crystal structure of QL-nanoKAZ

![Fig 6. Crystal structure of QL nanoKAZ](https://doi.org/10.1371/journal.pone.0272992.g006)

Fig 6. Crystal structure of QL-nanoKAZ. A. Comparison of the crystal structures between nanoKAZ and QL-nanoKAZ. A superimposed structure of QL-nanoKAZ (green, PDB ID: 7VSX) on that of nanoKAZ (yellow, PDB ID: 5B0U). Red color in QL-nanoKAZ and blue color in nanoKAZ indicate the differences in structure at the α3-helices and Tyr 109, respectively. B. The amino acid residues around Tyr 109 in QL-nanoKAZ and nanoKAZ. A cartoon representation of QL-nanoKAZ (green) superimposed on nanoKAZ (yellow) around Tyr 109. Red- and blue colors at the α3-helices and Tyr 109 are from QL-nanoKAZ and nanoKAZ, respectively.

![Fig 7. Comparison of the secondary structures between nanoKAZ and QL-nanoKAZ](https://doi.org/10.1371/journal.pone.0272992.g007)

Fig 7. Comparison of the secondary structures between nanoKAZ and QL-nanoKAZ. The amino acid sequences of nanoKAZ and QL-nanoKAZ are shown with their positions of the secondary structure, and the letters highlighted in orange indicate the substituted 16 amino acid residues in wild KAZ to prepare reverse mutations of nanoKAZ. The cylinders and arrows indicate the regions of α-helices (yellow, α1–α4) and β-strands (blue, β1–β11), respectively. The green in the cylinder (α3) and the arrows (β6 and β7) in QK-nanoKAZ indicate the structural differences compared to nanoKAZ. Tyr 109 is highlighted in red.
was determined, showing that the reverse mutations at V18Q and V27L in nanoKAZ causes local structural changes and might enhance the binding affinity to CTZ and lead to efficient oxidized of CTZ with O2 to emit light.

Supporting information
S1 Fig. Photograph of QL-nanoKAZ crystal for structural analysis.
(DOC)
S1 Table. Primer list used for site-directed mutagenesis to prepare reverse mutant genes for nanoKAZ by PCR.
(DOC)
S2 Table. Purification of QL-nanoKAZ from 800 mL of cultured E. coli cells using a Ni-chelate column.
(DOC)
S1 Raw images.
(PDF)

Acknowledgments
The authors thank Dr. H. Hojo (Institute for Protein Research, Osaka University) for determining the protein concentration by amino acid composition analysis, Dr. T. Suzuki (Aichi Gakuin University) for visualizing the secretion of QL-nanoKAZ stably expression in CHO-K1 cells, and Dr. T. Nakatsu (Wakayama Medical University) for valuable discussions of the binding cavity of CTZ in the nanoKAZ molecule. This work is based on experiments performed at SPring-8, with the approval of the Japan Synchrotron Radiation Research Institute (Proposal No. 20160018). The authors thank Drs. H. Niwa, N. Sakai, and T. Umehara, and the beamline staffs for the synchrotron radiation experiments at SPring-8.

Author Contributions
Conceptualization: Satoshi Inouye, Mikako Shirouzu, Takamitsu Hosoya.
Data curation: Satoshi Inouye, Jun-ichi Sato, Yuiko Sahara-Miura, Yuri Tomabechi, Yuto Sumida, Shun-ichi Sekine.
Formal analysis: Satoshi Inouye, Jun-ichi Sato, Yuiko Sahara-Miura, Yuri Tomabechi, Yuto Sumida, Shun-ichi Sekine.
Investigation: Satoshi Inouye, Jun-ichi Sato, Yuiko Sahara-Miura, Yuri Tomabechi, Yuto Sumida, Shun-ichi Sekine.
Methodology: Satoshi Inouye, Jun-ichi Sato, Yuiko Sahara-Miura, Yuto Sumida.
Project administration: Satoshi Inouye, Mikako Shirouzu, Takamitsu Hosoya.
Supervision: Satoshi Inouye, Mikako Shirouzu, Takamitsu Hosoya.
Writing – original draft: Satoshi Inouye.
Writing – review & editing: Satoshi Inouye, Yuri Tomabechi, Mikako Shirouzu, Takamitsu Hosoya.
References

1. Johnson FH, Stachel H-D, Shimomura O, Haneda Y. Partial purification of luminescence system of a deep-sea shrimp, Hoplophorus gracilorostris, In Bioluminescence in Progress (Johnson F. H. & Haneda Y., Eds.) Princeton University Press, Princeton, NJ. (1966) pp 523–532.

2. Shimomura O, Masugi T, Johnson FH, Haneda Y. Properties and reaction mechanism of the bioluminescence system of the deep-sea shrimp Hoplophorus gracilorostris. Biochemistry 17 (1978) 994–998. https://doi.org/10.1021/bi00599a008 PMID: 629957

3. Inouye S, Watanabe K, Nakamura H, Shimomura O. Secretional luciferase of the luminous shrimp Ophelia gracilorostris, cDNA cloning of a novel imidazopyrazinone luciferase. FEBS Lett. 481 (2000) 19–25. https://doi.org/10.1016/s0014-5793(00)01963-3

4. Inouye S, Sasaki S. Overexpression, purification and characterization of the catalytic component of Ophelia luciferase in the deep-sea shrimp, Ophelia gracilorostris. Protein Express. Purif. 56 (2007) 261–268. https://doi.org/10.1016/j.pep.2007.08.002 PMID: 17900925

5. Inouye S, Sato J, Sahara-Miura Y, Yoshida S, Kurakata H, Hosoya T. C6-Deoxy coelenterazine analogues as an efficient substrate for glow luminescence reaction of nanoKAZ: the mutated catalytic 19 kDa component of Ophelia luciferase. Biochem. Biophys. Res. Commun. 437 (2013) 23–28. https://doi.org/10.1016/j.bbrc.2013.06.026 PMID: 23792095

6. Inouye S, Sahara-Miura Y, Sato J, Suzuki T. Codon optimization of genes for efficient protein expression in mammalian cells by selection of only preferred human codons. Protein Express. Purif. 109 (2015) 47–54. https://doi.org/10.1016/j.pep.2015.02.002 PMID: 25665506

7. Inouye S, Sato J, Sahara-Miura Y, Yoshida S, Hosoya T. Luminescence enhancement of the catalytic 19 kDa protein (KAZ) of Ophelia luciferase by three amino acid substitutions. Biochem. Biophys. Res. Comm. 445 (2014) 157–162. https://doi.org/10.1016/j.bbrc.2014.01.133 PMID: 24491536

8. Inouye S, Sato J, Sahara-Miura Y, Hosoya T, Suzuki T. Unconventional secretion of the mutated 19 kDa protein of Ophelia luciferase (nanoKAZ) in mammalian cells. Biochem. Biophys. Res. Comm. 450 (2014) 1313–1319. https://doi.org/10.1016/j.bbrc.2014.06.140 PMID: 25019994

9. Hall MP, Unch J, Binkowski BF, Valley MP, Butler BL, Wood MG, et al. Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate. ACS Chem. Biol. 7 (2012) 1848–1857. https://doi.org/10.1021/cb3002478 PMID: 22894855

10. Tomabechi Y, Hosoya T, Ehara H, Sekine S, Shirouzu M, Inouye S. Crystal structure of nanoKAZ: the mutated 19 kDa component of Ophelia luciferase catalyzing the bioluminescence reaction with coelenterazine. Biochem. Biophys. Res. Comm. 470 (2016) 88–93. https://doi.org/10.1016/j.bbrc.2015.12.123 PMID: 26746005

11. Inouye S, Shimomura O. The use of Renilla luciferase, Ophelia luciferase, and apoaequorin as bioluminescent reporter protein in the presence of coelenterazines analogues as substrate. Biochem. Biophys. Res. Comm. 233 (1997) 349–353. https://doi.org/10.1006/bbrc.1997.6452 PMID: 9144537

12. Nakamura H, Wu C, Mura A, Inouye S. Efficient bioluminescence of bisdeoxycoelenterazine with the luciferase of a deep-sea shrimp Oplophorus. Tetrahedron Lett. 38 (1997) 6405–6406.

13. Inouye S, Sahara-Miura Y, Sato J, Limori R, Yoshida S, Hosoya T. Expression, purification and luminescence properties of coelenterase-utilizing luciferases from Renilla, Ophelia and Gaussia: Comparison of substrate specificity for C2-modified coelenterazines. Protein Express. Purif. 88 (2013) 150–156. https://doi.org/10.1016/j.pep.2012.12.006 PMID: 23274053

14. Shimomura O, Flood PR, Inouye S, Bryan B, Shimomura A. Isolation and properties of the luciferase stored in the ovary of the scyphozoan medusa Periphylla Periphylla. Biol. Bull. 201 (2001) 339–347. https://doi.org/10.2307/1543612 PMID: 11751246

15. Yeh H-W, Karmach O, Ji A, Carter D, Martins-Green MM, Al H-W. Red-shifted luciferase–luciferin pairs for enhanced bioluminescence imaging. Nat. Methods 14 (2017) 971–974. https://doi.org/10.1038/nmeth.4400 PMID: 28869756

16. Tannous BA, Kim D-E, Fernandez JL, Weissleder R, Breakefield XO. Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol. Ther. 11 (2005) 435–443. https://doi.org/10.1016/j.ymtb.2004.10.016 PMID: 15727940

17. Lorenz WW, McCann RO, Longiur M, Cormier MJ. Isolation and expression of a cDNA encoding Renilla reniformis luciferase. Proc. Natl. Acad. Sci. USA 88 (1991) 4438–4442. https://doi.org/10.1073/pnas.88.10.4438 PMID: 1674607

18. Loening AM, Wu AM, Gambhir SS. Red-shifted Renilla reniformis luciferase variants for imaging in living subjects. Nat. Methods 4 (2007) 641–643. https://doi.org/10.1038/nmeth0707 PMID: 17618292

19. Inouye S, Sumida Y, Tomabechi Y, Taguchi J, Shirouzu M, Hosoya T. Chiral deaza-coelenterazine analogs for probing a substrate-binding site in the Ca2+-binding photoprotein aequorin. PLOS ONE 16 (2021) e0251743. https://doi.org/10.1371/journal.pone.0251743 PMID: 34115795
Reverse mutants of nanoKAZ with coelenterazine as preferred substrate

20. Inouye S, Iimori R, Sahara Y, Hisada S, Hosoya T. Application of new semisynthetic aequorins with long half-decay time of luminescence to G-protein-coupled receptor assay. Anal. Biochem. 407 (2010) 247–252. https://doi.org/10.1016/j.ab.2010.08.025 PMID: 20800051

21. Inouye S. Single-step purification of recombinant Gaussia luciferase from serum-containing culture medium of mammalian cells. Protein Expr. Purif. 141 (2018) 32–38. https://doi.org/10.1016/j.pecp.2017.09.001 PMID: 28888757

22. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77 (1989) 51–59. https://doi.org/10.1016/0378-1119(89)90358-2 PMID: 2744487

23. Inouye S, Sahara Y. Soluble protein expression in E. coli cells using IgG binding domain of protein A as a solubilizing partner in the cold induced system. Biochem. Biophys. Res. Commun. 376 (2008) 448–453. https://doi.org/10.1016/j.bbcr.2008.08.149 PMID: 18789309

24. Inouye S, Sahara Y. Expression and purification of the calcium binding photoprotein mitrocomin using ZZ-domain as a soluble partner in E. coli cells. Protein Express. Purif. 66 (2009) 52–57. https://doi.org/10.1016/j.pecp.2009.01.010 PMID: 19367679

25. Inouye S, Sahara-Miura Y, Sato J, Suzuki T. Codon optimization of genes for efficient protein expression in mammalian cells by selection of only preferred human codons. Protein Express. Purif. 109 (2015) 47–54. https://doi.org/10.1016/j.pecp.2015.02.002 PMID: 25665506

26. Inouye S, Suzuki T. Protein expression of preferred human codon-optimized Gaussia luciferase genes with an artificial open-reading frame in mammalian and bacterial cells. Protein Express. Purif. 128 (2016) 93–100. https://doi.org/10.1016/j.pecp.2016.08.006 PMID: 27506135

27. Inouye S, Hojo H. Revalidation of recombinant aequorin as a light emission standard: Estimation of specific activity of Gaussia luciferase. Biochem. Biophys. Res. Commun. 507 (2018) 242–245. https://doi.org/10.1010.1015.j.bbcr.2018.11.015 PMID: 30424878

28. Inouye S, Nakamura M, Taguchi J, Hosoya T. Identification of a novel oxidation product from yellow fluorophore in the complex of apoPholasin and dehydrocoelenterazine. Bioorg. Med. Chem. Lett. 30 (2020) 127435. https://doi.org/10.1016/j.bmcl.2020.127435 PMID: 32717370

29. Ueno G, Kanda H, Hirose K, Ida R, Kumasaka T, Yamamoto M. RIKEN structural genomics beamlines. Acta Cryst. D66 (2010) 125–132. https://doi.org/10.1107/S0907444909047337 PMID: 20124692

30. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. J. Appl. Cryst. 40 (2007) 658–674. https://doi.org/10.1107/S0021889807021206 PMID: 19461840

31. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, et al. PHENIX: a comprehensive python based system 436 for macromolecular structure solution. Acta Cryst. D66 (2010) 213–221. https://doi.org/10.1107/S0907444909052925 PMID: 20124702

32. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Cryst. D66 (2010) 486–501. https://doi.org/10.1107/s0907444910007493 PMID: 20383002

33. Suzuki T, Kondo C, Kanamori T, Inouye S. Video rate bioluminescence imaging of secretory proteins in living cells: Localization, secretory frequency, and quantification. Anal. Biochem. 415 (2011) 182–189. https://doi.org/10.1016/j.ab.2011.03.039 PMID: 21477579

34. Suzuki T, Kanamori T, Inouye S. Quantitative visualization of synchronized insulin secretion from 3D-cultured cells. Biochem. Biophys. Res. Commun. 486 (2017) 886–892. https://doi.org/10.1010.1015.j.bbcr.2017.03.015 PMID: 28342877

35. Inouye S, Nakamura M, Hosoya T. Formation of coelenteramine from 2-peroxycoelenterazine in the Ca2+-binding photoprotein aequorin. Photochem. Photobiol. (2021) https://doi.org/10.1111/php.13590 PMID: 34971002

36. Kumar S, Harrylock M, Walsh KA, Cormier MJ, Charbonneau H. Amino acid sequence of the Ca2+-triggered luciferin binding protein of Renilla reniformis. FEBS Lett. 268 (1990) 287–290. https://doi.org/10.1016/0014-5793(90)81029-n

37. Inouye S. Expression, purification and characterization of calcium-triggered luciferin-binding protein of Renilla reniformis. Protein Expr. Purif. 52 (2007) 66–73. https://doi.org/10.1016/j.pecp.2006.07.028 PMID: 16997571

38. Stepanyuk GA, Liu Z-J, Markova SS, Frank LA, Lee J, Vysotski ES, et al. Crystal structure of coelenterazine-binding protein from Renilla muelleri at 1.7 Å: Why it is not a calcium-regulated photoprotein. Photochem. Photobiol. Sci. 7 (2008) 442–447. https://doi.org/10.1039/b716535h